Loading…
Loading…
As of 20 Nov 2026: ADVENZYMES ₹290.45 (m-cap ₹3,253 Cr, P/E 19.0) vs ENNATURE ₹167.65 (m-cap ₹374 Cr, P/E 373.9). Compare ROE, ROCE, growth, debt, dividends and 1-year returns.
As of · NSE prices; ratios from company filings
| Metric | ADVENZYMES | ENNATURE |
|---|---|---|
| Share price | ₹290.45 | ₹167.65 |
| Day change | −1.96% | −6.03% |
| Market cap | ₹3,253 Cr | ₹374 Cr |
| P/EPrice ÷ trailing 12-month earnings per share; blank for a loss. | 19.0 | 373.9 |
| P/BPrice ÷ book value per share. | 2.0 | — |
| ROEReturn on equity. | 10.5% | — |
| ROCEReturn on capital employed. | 14.0% | — |
| Sales growth (3Y CAGR) | 11.3% | — |
| Profit growth (3Y CAGR) | 12.5% | — |
| Debt to equity | 0.02 | 0.00 |
| Dividend yield | 0.46% | 0.00% |
| 1-year price return | −10.7% | — |
| Promoter holding | 43.2% | 59.6% |
| Industry | Biotechnology | Biotechnology |
Open in the compare tool for price charts from one month to five years, scorecards and more companies.
Each line states which company has the higher or lower figure; none of them is a recommendation.
Advanced Enzyme Technologies Ltd is larger, with a market cap of ₹3,253 Cr against ₹374 Cr for Ennature Bio Pharma Ltd as of 20 Nov 2026 — about 8.7 times the size.
Advanced Enzyme Technologies Ltd trades at a P/E of 19.0 against 373.9 for Ennature Bio Pharma Ltd as of 20 Nov 2026. A lower P/E alone does not make a share cheaper in value terms: growth, return on capital and debt differ between companies.
Jivani Markets does not give buy, sell or hold recommendations and is not a SEBI-registered investment adviser or research analyst. The table on this page lays out the facts side by side — price, valuation, returns on capital, growth, debt, dividends and promoter holding — so you can weigh them against your own goals, or with a SEBI-registered adviser.
Prices refresh every few minutes during market hours and ratios update when the companies report results. Each number is the same one shown on the two stock pages.